Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease
Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
AbstractSickle Cell Disease (SCD) is the most common genetic disease in the United States. Symptoms result from formation of sickle hemoglobin (HbS), which polymerizes and obstructs vasculature. Voxelotor, a HbS polymerization inhibitor, was granted accelerated approval by the Food and Drug Administration in 2019 for chronic treatment of SCD. While...
Alternative Titles
Full title
Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2650242725
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2650242725
Other Identifiers
ISSN
0735-6757
E-ISSN
1532-8171
DOI
10.1016/j.ajem.2021.12.031
